DaVita (DVA)
(Delayed Data from NYSE)
$149.96 USD
+1.08 (0.73%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $149.99 +0.03 (0.02%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$149.96 USD
+1.08 (0.73%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $149.99 +0.03 (0.02%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Should Value Investors Buy DaVita HealthCare (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Masimo (MASI) Releases Favorable Findings on Pulse Oximetry
by Zacks Equity Research
Researchers on probe discover that the use of Masimo's (MASI) SpHb was related to the lower rate of postoperative transfusion, minimal duration of ICU stay and other better outcomes.
Encompass Health (EHC) to Spin Off Unit to Streamline Business
by Zacks Equity Research
Encompass Health (EHC) is exploring strategic alternatives to split its home health and hospice business from the original corporate structure to streamline operations.
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Should Value Investors Buy DaVita HealthCare (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Choose DaVita (DVA) Stock Now?
by Zacks Equity Research
Is DaVita (DVA) a great pick from the value investor's perspective right now? Read on to know more.
Why DaVita (DVA) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider DaVita (DVA).
DaVita's (DVA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in DaVita (DVA).
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.
Allscripts' (MDRX) Veradigm Collaborates With HealthVerity
by Zacks Equity Research
Allscripts (MDRX) and HealthVerity will be committed toward catering to specific industry needs by helping clients design linked data solutions that are fit-for-purpose.
Here's Why You Should Hold NextGen (NXGN) in Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.
AngioDynamics (ANGO) Shows Solid Results from RAPID Database
by Zacks Equity Research
The RAPID study proved that AngioDynamics' (ANGO) AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses.
Is DaVita (DVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
Ecolab Introduces Exelerate TUFSOIL for Food Manufacturers
by Zacks Equity Research
Ecolab's (ECL) Exelerate TUFSOIL has been developed to increase production time and enhance cleaning outcomes to curb food safety risks and improve worker safety.
Becton Dickinson (BDX) Buys Medical Business Assets of CUBEX
by Zacks Equity Research
This should further boost BD's (BDX) Medical segment.
Encompass Health (EHC) to Build Rehabilitation Hub in Illinois
by Zacks Equity Research
Encompass Health (EHC) to construct an inpatient rehabilitation hospital with a capacity of 40 in Shiloh Illinois, which will be run as a joint venture with BJC HealthCare.
Is DaVita HealthCare (DVA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
New Strong Buy Stocks For November 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
The Zacks Analyst Blog Highlights: United Natural Foods, The Boston Beer Company, DaVita, Owens & Minor and Primo Water Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: United Natural Foods, The Boston Beer Company, DaVita, Owens & Minor and Primo Water Corp
The Zacks Analyst Blog Highlights: FedEx, Whirlpool, The Boston Beer Company, Laboratory Corporation of America and DaVita
by Zacks Equity Research
The Zacks Analyst Blog Highlights: FedEx, Whirlpool, The Boston Beer Company, Laboratory Corporation of America and DaVita
6 Stocks Near 52-Week Highs Poised to Appreciate Further
by Anirudha Bhagat
Investors target stocks that have been on a bullish run, lately. Stocks seeing price strength have higher chances of carrying the momentum ahead.
Acadia Healthcare (ACHC) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Acadia Healthcare (ACHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
5 Safe Stocks to Sail Through the US Election Uncertainties
by Sreoshi Bera
Rise in coronavirus cases and uncertainties revolving around the election might keep markets volatile for some time. Here are five stocks to invest in and play safe.